February 27, 2020 | Vensana in the News

Vensana—Is Medtech Investing on the Rebound?

20

Novel FDA PMA & de novo 510k approvals

55

U.S. Commercial Product Launches

39

Level I Clinical Trials

29

Strategic Financings

30

Exits by IPO or M&A